Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.

The Journal of pharmacology and experimental therapeutics - 1 Mar 2018

Hilberg Frank, Tontsch-Grunt Ulrike, Baum Anke, Le Anh T, Doebele Robert C, Lieb Simone, Gianni Davide, Voss Tilman, Garin-Chesa Pilar, Haslinger Christian, Kraut Norbert

Abstract excerpt

The triple-angiokinase inhibitor nintedanib is an orally available, potent, and selective inhibitor of tumor angiogenesis by blocking the tyrosine kinase activities of vascular endothelial growth factor receptor (VEGFR) 1-3, platelet-derived growth factor receptor (PDGFR)-α and -β, and fibroblast growth factor receptor (FGFR) 1-3. Nintedanib has received regulatory approval as second-line treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogenes

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Mas

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29263244
DOI: 10.1124/jpet.117.244129
PMCID: PMC6040086

Genes

FGFR2
RET
CCDC6
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.PMID 29263244Read ↗

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast CancerSemantic proximity Read ↗

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.Semantic proximity Read ↗

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.Semantic proximity Read ↗

<i><scp>FGFR</scp></i> gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanibSemantic proximity Read ↗

Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cellsSemantic proximity Read ↗

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsSemantic proximity Read ↗

RAS Inhibitor RMC-7977 Blocks Vascular Overgrowth of NRASQ61R Mutant Endothelial Cells.Semantic proximity Read ↗

Inhibiting TRK Proteins in Clinical Cancer TherapySemantic proximity Read ↗

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.Semantic proximity Read ↗

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.Semantic proximity Read ↗

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.Semantic proximity Read ↗

A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.